Contact us Demo our platform

Case Study

Hepatitis B Virus Infection Dysregulates Lipid Biosynthesis Pathways

The results from this study demonstrate how global metabolomics can be employed to identify metabolic targets that play a role in chronic HBV infection and potentially other hepatic or viral diseases.

This platform will allow the identification of novel biomarkers (metabolites) that might otherwise go undetected that can be used as therapeutic targets or as biomarkers of chronic HBV infection severity.

Talk With An Expert About Your Project

This platform will allow the identification of novel biomarkers (metabolites) that might otherwise go undetected that can be used as therapeutic targets or as biomarkers of chronic HBV infection severity.

Talk With An Expert About Your Project

The Challenge: Decipher the Interaction Between the Host’s Hepatic Lipid Metabolism and HBV Infection

Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV). For many people, hepatitis B is a short-term illness with mild symptoms, including fatigue, poor appetite, stomach pain, nausea, and jaundice. Unfortunately for others, hepatitis B can become a long-term chronic infection that can lead to serious, life-threatening health issues like liver failure, liver cancer, or cirrhosis. HBV is a global public health threat. According to the World Health Organization (WHO), the worldwide estimated prevalence of HBV infection is 3.5%, with 257 million people living with the chronic infection.1

A hallmark of chronic HBV infection is the high circulating levels of hepatitis B surface antigen (HBsAg) particles. Therefore, sustained low levels of HBsAg particles are considered an important clinical endpoint for HBV therapies and a vital goal of a functional cure. All viruses rely on host pathways for successful replication, and there is increasing interest in identifying these pathways as novel therapeutic targets for HBV drug discovery. However, the interaction between the host’s liver and HBV infection has not been completely elucidated.

Metabolon Insight: Metabolomics Helps Uncover a Link Between the Host and HBV Infection

Metabolon helped identify and characterize metabolomic changes that contribute to chronic HBV infection.2 The Metabolon Global Discovery Panel and the  Complex Lipids Targeted Panel were used to analyze liver tissue samples from HBV-infected and non-infected chimeric humanized mice.

The Solution: HBV Infection Leads to Metabolic Changes

The researchers worked with Metabolon to perform metabolomic analysis of liver tissue samples from uninfected and HBV-infected humanized chimeric liver (uPA/SCID) mice to determine if HBV infection modulates the host’s lipid pathways. A total of 1,698 metabolites were identified in liver tissue samples. Metabolomic profiling of livers from these mice revealed HBV-dependent changes in lipid metabolic pathways. HBV-dependent increases were observed in several long-chain free fatty acids (FFA), including monounsaturated, saturated, and polyunsaturated fatty acids. Myristate, palmitate, oleate, and linoleate are FFAs that were substantially upregulated in the HBV-infected samples compared to non-infected samples. HBV infection also resulted in statistically significant changes in the levels of metabolites within mevalonate and several other lipid pathways.

Given the observed HBV-dependent increases of FFA, the researchers also evaluated whether modulation of lipid biosynthesis pathways can inhibit HBV infection and HBsAg particle formation. They found that small molecules targeting enzymes within lipid biosynthetic pathways inhibited the secretion of HBsAg in HBV-infected human hepatic cells.

The Outcome: Metabolomics Can Identify Metabolic Targets That Drive Chronic HBV Infection

The role of metabolomics is instrumental in the identification and assessment of metabolites associated with disease progression or disease phenotyping. This study identified several novel lipid metabolic pathways dysregulated during HBV infection. Modulation of these lipid pathways offers new potential avenues for HBV treatments. The results from this study demonstrate how global metabolomics can be employed to identify metabolic targets that play a role in chronic HBV infection and potentially other hepatic or viral diseases. Metabolomics technology will allow the identification of novel biomarkers (metabolites) that might otherwise go undetected that can be used as therapeutic targets or as biomarkers of chronic HBV infection severity.

References

1. WHO. Global hepatitis report, 2017. Geneva 2017: World Health Organization; 2017.

2. Hyrina A, Burdette D, Song Z, et al. Targeting lipid biosynthesis pathways for hepatitis B virus cure. PLoS One. 2022;17(8):e0270273. Published 2022 Aug 4. doi:10.1371/journal.pone.0270273

Related Case Studies

See All Case Studies
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.